Research Topics
| J I ClarkSummaryAffiliation: Loyola University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Case report and brief review: IL-2-induced myocarditisRobert M Eisner
Department of Internal Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA
Cancer Invest 22:401-4. 2004..It may be reasonable to make the diagnosis on clinical grounds, while providing supportive care. Future investigation is required to better understand the pathophysiology and what factors may influence expression of this toxicity...
Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancerJoseph I Clark
Edward Hines, JR VA Hospital, Hines, IL 60411, USA
Med Oncol 30:358. 2013....
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508Joseph I Clark
Cardinal Bernardin Cancer Center, Loyola University Medical Center, Division of Hematology Oncology, 2160 South First Avenue, Maywood, IL 60153, USA
Cancer 116:424-31. 2010..We conducted a multicenter phase 2 trial to better define the clinical efficacy of thalidomide and temozolomide and the immune modulatory effects of thalidomide, when combined with temozolomide, in patients with metastatic melanoma...- Phase I adjuvant radiation with docetaxel in high-risk head and neck cancerJoseph I Clark
Department of Medicine, Division of Hematology Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA
Am J Clin Oncol 32:396-400. 2009..This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck... - Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancerJ I Clark
Edward Hines, JR VA Hospital, Hines, IL, USA
Lung Cancer 34:271-7. 2001.... - Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark
Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
J Immunother 30:839-46. 2007..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen... - Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinomaJ I Clark
Department of Medicine, Division of Hematology Oncology, Loyola University Medical Center Cardinal Bernardin Cancer Center, 2160 South First Avenue, Maywood, IL 60153, USA
Cancer 92:2334-40. 2001..The authors investigated the use of paclitaxel and carboplatin in a limited Phase II study in recurrent or metastatic SCCHN to evaluate tumor response, time to progression, survival, and toxicities of this regimen... - Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJoseph I Clark
Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
J Clin Oncol 21:3133-40. 2003..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)... - A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient populationJ I Clark
Edward Hines Jr VA Hospital, IL, USA
Ann Oncol 13:606-13. 2002..The identical regimen has shown promise in advanced melanoma... - Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-alpha in patients with advanced renal cell carcinomaJ I Clark
Edward Hines, Jr, Veterans Affairs Hospital, Hines, Illinois 60141, USA
Clin Cancer Res 5:2374-80. 1999..Despite the reasonable tolerability of this daily low-dose s.c. regimen, we conclude that this regimen is an ineffective treatment in metastatic renal cell carcinoma patients who are incapable of tolerating high-dose i.v. IL-2... - Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott
Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
J Clin Oncol 23:133-41. 2005..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma... - New therapeutic strategies for the treatment and prevention of head and neck cancerM W Lingen
Department of Pathology, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
Expert Opin Investig Drugs 9:2855-72. 2000..Finally, we will discuss the rationale for the use of anti-angiogenic agents as one possible means of developing new chemopreventive protocols that result in reduced toxicity while maintaining similar clinical efficacies... - Neoadjuvant therapy: an emerging concept in oncologyTawee Tanvetyanon
Division of Hematology Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA
South Med J 98:338-44. 2005..To date, the survival benefits of neoadjuvant therapy for resectable non-small cell lung, esophageal, gastric, and prostate cancer remains under investigation... - Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026Laura F Hutchins
Division of Hematology Oncology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
Cancer 110:2269-75. 2007..Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma. Endpoints were 6-month progression-free survival rate, response rate, and toxicity... - Posterior marginal mandibulectomy in the management of cancer of the oral cavity and oropharynxGuy J Petruzzelli
Department of Otolaryngology Head and Neck Surgery, Division of Plastic and Reconstructive Surgery, Loyola University Medical Center, Maywood, IL 60153, USA
Otolaryngol Head Neck Surg 129:713-9. 2003..To review the history and surgical technique with emphasis on functional as well as oncologic outcomes... - Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Cancer 113:2139-45. 2008..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma... - Metastatic renal cell carcinomaRobert C Flanigan
Department of Urology, Loyola University Medical Center, Cardinal Bernardin Cancer Center and Hines VA Hospital, Maywood, IL 60153, USA
Curr Treat Options Oncol 4:385-90. 2003.... - Nephrectomy in metastatic renal cell carcinomaSteven C Campbell
Department of Urology, The Cardinal Bernardin Cancer Center, Loyola University Medical Center, Hines VA Hospital, 2160 South 1st Avenue, Building 54, Room 237, Maywood, IL 60153, USA
Curr Treat Options Oncol 4:363-72. 2003.... - Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patientsE Y Nikitina
Cardinal Bemardin Cancer Center, Loyola University Medical Center, Maywood, Illinois 60153, USA
Clin Cancer Res 7:127-35. 2001..These data demonstrate that DCs transduced with the wild-type p53 gene were able to induce a specific antitumor immune response. This offers a new promising approach to immunotherapy of cancer... - Passive seeding in metanephric adenoma: a review of pseudometastatic lesions in perinephric lymph nodesGladell P Paner
Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
Arch Pathol Lab Med 129:1317-21. 2005..We conclude that this phenomenon is understudied and underrecognized and can easily be mistaken for metastasis... - Metanephric adenosarcoma in a young adult: morphologic, immunophenotypic, ultrastructural, and fluorescence in situ hybridization analyses: a case report and review of the literatureM M Picken
Department of Pathology, Loyola University Medical Center, Chicago, Illinois 60153, USA
Am J Surg Pathol 25:1451-7. 2001..We conclude that the spectrum of metanephric neoplasia should be expanded to include malignant stromal variants, and we propose the term "metanephric adenosarcoma" for the present case... - Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019Kathy S Albain
Loyola University Stritch School of Medicine, Maywood, IL, USA
J Clin Oncol 20:3454-60. 2002..These results also justify use of the SWOG-9019 approach as a control arm in ongoing phase III trials... - Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyEzra E W Cohen
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA University of Chicago Cancer Research Center, Chicago, IL, USA
Lancet Oncol 10:247-57. 2009..In this multi-institutional phase I/II study we combined an EGFR inhibitor, erlotinib, with an anti-VEGF antibody, bevacizumab... - A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanomaFrederick Locke
Department of Medicine, University of Chicago, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 65:509-14. 2010..GM-CSF has a theoretical advantage of immune potentiation. These considerations supported the study of oxaliplatin, docetaxel, and GM-CSF in patients with advanced melanoma... - Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patientsD M Lathers
Research Service, Hines Veterans Affairs Hospital, Hines, Illinois 60141, USA
Hum Immunol 62:1282-93. 2001..Although no clinical responses were observed, results of these pilot studies showed that 25-hydroxyvitamin D(3) reduced the presence of immune suppressive CD34(+) cells and improved immune competence of HNSCC patients... - Metastatic juxtaglomerular cell tumor in a 52-year-old manXiuzhen Duan
Department of Pathology, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153, USA
Am J Surg Pathol 28:1098-102. 2004..In consideration of the characteristic morphologic features, immunohistochemistry, and the presence of rhomboid crystals of proto-renin, the diagnosis was modified to malignant juxtaglomerular cell tumor... - Xp11.2 translocation renal cell carcinoma with very aggressive course in five adultsPaul N Meyer
Department of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA
Am J Clin Pathol 128:70-9. 2007..Various treatments met with minimal success. Unlike pediatric patients, the adult patients followed a rapidly terminal course, with a mean survival of 18 months after diagnosis (range, 10-24 months)... - A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancerRichard T Lee
Department of Medicine, Section of Hematology Oncology, The University of Chicago, IL 60637, USA
Clin Genitourin Cancer 6:21-4. 2008..SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death... - Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case reportJanet C Ruzich
Hematology and Oncology, Cardinal Bernadin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, Illinois, USA
Head Neck 24:406-10. 2002..RESULTS: The patient obtained a complete response after six cycles of carboplatin and paclitaxel. CONCLUSIONS: The use of carboplatin and paclitaxel in the setting of metastatic salivary gland cancer is a viable option... - Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosisMohtashim Naeem
Loyola University Medical Center, Maywood, IL, USA
Hum Pathol 33:1182-7. 2002..Furthermore, determination of c-kit in SCLC may have a prognostic value in SCLC patients... - Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJeffrey A Sosman
Vanderbilt Ingram Cancer Center Vanderbilt, University Medical Center, Section of Hematology Oncology, 777 Preston Research Bldg, Nashville, TN 37232 6307, USA
J Clin Oncol 26:2292-8. 2008..We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial... - Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin
City of Hope National Medical Center, Duarte, California 91010 3000, USA
Clin Cancer Res 13:3312-9. 2007..This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics... - Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3Deanne M R Lathers
Research Service (151, Ralph H. Johnson Veterans Affairs Medical Center, 109 Bee Street, SC 29401-5799, Charleston, USA
Cancer Immunol Immunother 53:422-30. 2004..In contrast, 25-hydroxyvitamin D(3) treatment did not modulate plasma IL-1beta, IL-2, IL-4, IL-6, IL-10, GM-CSF, or TGF-beta levels... - A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007Francis P Worden
Department of Internal Medicine, Division of Medical Oncology, University of Michigan, Ann Arbor, Michigan 48109 0848, USA
Cancer 107:319-27. 2006..To validate these results and to determine the feasibility of this combination, a Phase II study was conducted by the Southwest Oncology Group (SWOG S0007)... - Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxelMartin J Edelman
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
Clin Cancer Res 10:5022-6. 2004..CONCLUSIONS: Sequential therapy, as used in this study, resulted in comparable efficacy to previous Southwest Oncology Group trials of two drug combinations in this population; however, it failed to meet criteria for further study... - Renal tumor with overlapping distal nephron morphology and karyotypeValerie Lindgren
Department of Pathology, University of Illinois at Chicago, Chicago, Ill, USA
Arch Pathol Lab Med 128:1274-8. 2004....